Loading clinical trials...

Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis | Clinical Trials | Clareo Health

COMPLETEDPhase 2/3NCT01912716

Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis

It is now established that indomethacin, a non-steroidal anti-inflammatory drug, at a dose of 100 mg, is effective in reducing the frequency and severity of pancreatitis (inflammation of the pancreas)...

Lead sponsor: Indiana University•6 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 4

Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis

NCT07088757 · Post-ERCP Pancreatitis

RECRUITINGNA

Early Pancreatic Stent Placement for Preventing PEP

NCT06250803 · Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis

TERMINATEDPhase 3

Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.

NCT03749590 · Post-ERCP Pancreatitis

UNKNOWNNA

Comparison Of Loop-Tip Wire Vs Tradictional Technique In The Cannulation Of The Common Bile Duct

NCT01771419 · Post-ERCP Pancreatitis

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 5, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2/PHASE3

Enrollment1,037

Start dateJul 2013

Last updatedJul 5, 2019

Condition

Post-ERCP Pancreatitis

Locations shown

Indiana University Health

Indianapolis, Indiana

Beth Israel Deaconess Medical Center

Boston, Massachusetts

University of Michigan Medical Center

Ann Arbor, Michigan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 5, 2019Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions